This Week in CRC Research — July 12, 2026
Weekly colorectal cancer research intelligence
kras
A collection of 71 issues
KRAS, NRAS, and BRAF mutation patterns in Chile
Skip to content
The CRC Digest
KRAS, NRAS, and BRAF mutation patterns in Chile
Real-world data from 999 Chilean patients characterized the frequency and sex-specific distribution of KRAS, NRAS, and BRAF mutations. (Journal of Gastrointestinal Oncology)
This content is informational only and does not constitute medical advice.
Always consult your
CRC Research Update — July 06, 2026
Today's colorectal cancer research highlights
CRC Research Finding
Skip to content
The CRC Digest
Dihydroartemisinin targets KRASG12D to overcome immunotherapy resistance
Anti-malaria drug selectively downregulates KRASG12D mutant protein and enhances regorafenib plus anti-PD-1 in preclinical liver metastasis models. (Cell Death & Disease)
This content is informational only and does not constitute medical advice.
Always consult your oncologist or
New FAK inhibitor shows promise in KRAS-mutant colorectal cancer
Skip to content
The CRC Digest
New FAK inhibitor shows promise in KRAS-mutant colorectal cancer
Researchers designed a focal adhesion kinase (FAK) inhibitor (compound 7g) that demonstrated antiproliferative activity in KRAS-mutant HCT116 colorectal cancer cells and showed 66.5% tumor growth inhibition in mouse models. (Bioorg Chem)
This content is
CRC Research Update — July 02, 2026
Today's colorectal cancer research highlights
KRAS Mutations Predict Worse Outcomes After Liver Metastasis Surgery
Skip to content
The CRC Digest
KRAS Mutations Predict Worse Outcomes After Liver Metastasis Surgery
In 190 patients who had curative liver surgery for colorectal metastases, KRAS mutations (37.9% of patients) were associated with significantly worse overall and recurrence-free survival and more aggressive recurrence patterns. (Surgery Today)
This content
CRC Research Update — June 25, 2026
Today's colorectal cancer research highlights
Colonoscope-Derived Mucus Detects KRAS Mutations in Precancerous Lesions
Skip to content
The CRC Digest
Colonoscope-Derived Mucus Detects KRAS Mutations in Precancerous Lesions
A prospective pilot study found that mucus collected from the colonoscope sheath during routine colonoscopy serves as a high-fidelity source of cell-free DNA for detecting KRAS-mutated colorectal neoplasia. (Translational Oncology)
This content is informational only and
KRAS G13C Inhibitor Reveals Unique Biology of Codon 13 Mutations
Skip to content
The CRC Digest
KRAS G13C Inhibitor Reveals Unique Biology of Codon 13 Mutations
RMC-8839, a covalent KRAS G13C inhibitor, induced tumor regressions in selected xenograft models, but one-third of cell lines showed incomplete pathway suppression, revealing that codon 13-mutant RAS differs from other KRAS mutations with decreased